I'd also add it's a high beta stock getting crunched in line with the market downturn.
Check out Capricor Therapeutics - 20% rise yesterday off the back of partnering with a dominant Japanese pharma player. Just another sign of the exosome market heating up and it augurs well for our preliminary partnership with Showa Denko (also Japanese). Finally, on the academic/research side, over 400 exosome papers have been published in 2022 so far, which represents strong growth relative to the ~9000 papers in 2021.
EX1 Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
